Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation

Jun Yan^{1

2

3}, Qingnan Zhao³, Konrad Gabrusiewicz⁴, Ling-Yuan Kong⁴, Xueqing Xia³, Jian Wang⁵, Martina Ott⁴, Jingda Xu⁶, R Eric Davis⁶, Longfei Huo³, Ganesh Rao⁴, Shao-Cong Sun⁷, Stephanie S Watowich⁷, Amy B Heimberger⁸, Shulin Li⁹

Affiliations

¹ Center for Brain Disorders Research, Capital Medical University, Beijing, 100069, China.
² Beijing Institute for Brain Disorders, Beijing, 100069, China.
³ Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁴ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁵ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁶ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁷ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁸ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. aheimber@mdanderson.org.
⁹ Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. sli4@mdanderson.org.

PMID: 30770835
PMCID: PMC6377651
DOI: 10.1038/s41467-019-08770-5

Published Erratum

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation

Jun Yan et al. Nat Commun. 2019.

. 2019 Feb 15;10(1):862.

doi: 10.1038/s41467-019-08770-5.

Authors

Affiliations

¹ Center for Brain Disorders Research, Capital Medical University, Beijing, 100069, China.
² Beijing Institute for Brain Disorders, Beijing, 100069, China.
³ Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁴ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁵ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁶ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁷ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
⁸ Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. aheimber@mdanderson.org.
⁹ Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. sli4@mdanderson.org.

PMID: 30770835
PMCID: PMC6377651
DOI: 10.1038/s41467-019-08770-5

Abstract

The original version of this Article contained errors in the author affiliations. Qingnan Zhao, Xueqing Xia, Longfei Huo and Shulin Li were incorrectly associated with Beijing Institute for Brain Disorders, 100069, Beijing, China.This has now been corrected in both the PDF and HTML versions of the Article.

PubMed Disclaimer

Erratum for

FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation.
Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE, Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. Yan J, et al. Nat Commun. 2019 Jan 25;10(1):448. doi: 10.1038/s41467-018-08271-x. Nat Commun. 2019. PMID: 30683885 Free PMC article.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation

Affiliations

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103⁺ dendritic cell differentiation

Authors

Affiliations

Abstract

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous